Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
May 21, 2015 11:15 ET
|
Adaptimmune Therapeutics plc
OXFORD, England and PHILADELPHIA, May 21, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat...
Adaptimmune Announces New Additions to Senior Clinical Management
May 20, 2015 14:02 ET
|
Adaptimmune Therapeutics plc
OXFORD, UK and PHILADELPHIA, May 20, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today...
Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting
May 13, 2015 09:59 ET
|
Adaptimmune Therapeutics plc
OXFORD, UK and PHILADELPHIA, May 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat...
Adaptimmune Announces Appointment of Vice President of Investor Relations
May 12, 2015 13:51 ET
|
Adaptimmune Therapeutics plc
OXFORD, UK and PHILADELPHIA, May 12, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today...
Adaptimmune Announces Closing of Initial Public Offering
May 11, 2015 11:49 ET
|
Adaptimmune Therapeutics plc
OXFORD, UK and PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq:ADAP) today announced the closing of its initial public offering of 11,250,000 American Depositary Shares (ADSs) at a...
Adaptimmune Announces Pricing of Initial Public Offering
May 06, 2015 07:00 ET
|
Adaptimmune Therapeutics plc
OXFORD, United Kingdom and PHILADELPHIA, May 6, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced the pricing of its initial public offering of 11,250,000 American...